Leap Therapeutics

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass., June 11, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation...

Leap Therapeutics Announces Oprhan Drug Designation of DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer

CAMBRIDGE, Mass., June 11, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, due to public health and safety concerns related to the outbreak of the novel coronavirus...

Leap Therapeutics Announces Changes to Virtual Format and Time for 2020 Annual Meeting of Stockholders

CAMBRIDGE, Mass., May 14, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2020. Leap First Quarter Highlights:...

Leap Therapeutics Reports First Quarter 2020 Financial Results

Facing a de-listing from NASDAQ and forced to abandon its second clinical asset due to a cash crunch, Leap has rebounded somewhat on the back of a collaboration/financing deal.

Looking Back In On Leap Therapeutics

Leap Therapeutics (LPTX) signs agreement with China-based BieGene granting the latter rights to develop its pipeline candidate, DKN-01. It also signs equity financing deals worth $27 million.

Leap Therapeutics Surges on License Agreement With BieGene

Leap Therapeutics (LPTX) news for Friday has LPTX stock soaring following a major deal with BeiGene for its DKN-01 antibody.
The post Leap Therapeutics News: LPTX Stock Takes a Massive 58% Leap on BeiGene Deal appeared first on InvestorPlace.

Leap Therapeutics News: LPTX Stock Takes a Massive 58% Leap on BeiGene Deal

Alder Biopharmaceuticals

American Woodmark

Columbia Sportswear Company

Dick's Sporting Goods

Cross the age-old barrier of low P/E investing. bet on these five stocks that boast rising P/E.

Use Rising P/E Strategy to Grab 5 Winning Stocks

Amarin Corporation Plc

AstraZeneca

Jazz Pharmaceuticals

Ligand Pharmaceuticals

Lexicon Pharmaceuticals

PhaseBio Pharmaceuticals Inc

Roche Holding AG

SAGE Therapeutics

Strongbridge Biopharma

Sanofi

Biotech stocks had an upweek, with the release of clinical trial results and the positive broader market sentiment offering ample support.

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

News for Leap Therapeutics Stock (LPTX)